Shionogi's naldemedine performs well in first COMPOSE Phase III
This article was originally published in Scrip
Shionogi's naldemedine (S-297995), an investigational peripherally acting mu-opioid receptor antagonist, has met primary and secondary endpoints in a phase III study for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain receiving opioid therapy.
You may also be interested in...
With oral naldemedine joining Purdue's pain portfolio, the company will look for ways to foster communication between patients and doctors about treatment for opioid-induced constipation.
In the latest instalment of our VC playbook series, In Vivo sits down with Roel Bulthuis, managing partner at INKEF Capital, to discuss the group’s approach to health care investing in Europe, the importance of funding a team not just a project and how life sciences venture capital is evolving with the emergence of health tech.
Our readers have been voting and the results have been counted. The winners of In Vivo's annual Deals Of The Year contest are ...